7781-10-4

Basic information

• Product Name: 4-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine
• Synonyms: 4-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine;4-Chloro-7-methyl-7H-pyrr...;6-Chloro-9-Methyl-7-deazapurine;NSC 102340
• CAS NO: 7781-10-4
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.59564
• Product Categories: Bases & Related Reagents;Heterocycles;Intermediates;Nucleotides;Heterocycle-Pyrimidine series
• Mol File: 7781-10-4.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 301.5 °C at 760 mmHg
• Flash Point: 136.2 °C
• Appearance: /
• Density: 1.43 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• CAS DataBase Reference: 4-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine(7781-10-4)
• EPA Substance Registry System: 4-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine(7781-10-4)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN2811
• Hazardous Substances Data: 7781-10-4(Hazardous Substances Data)

Usage

Chemical Properties

Light Brown Solid

Uses

4-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine is used in the preparation of indoline derivatives as PERK inhibitors.

Upstream product

• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 74-88-4 methyl iodide 
• 3680-71-5 7-deazahypoxanthine 

Downstream Products

• 7752-54-7 4-Amino-7-methyl-7H-pyrrolo<2,3-d>pyrimidin 
• 346600-34-8 (3-chloro-4-fluoro-phenyl)-(7-methyl-7H-pyrrolo [2,3-d]pyrimidin-4-yl)-amine 
• 865364-83-6 4-(3-chloro-4-fluoro-phenylamino)-7-methyl-5,7-dihydro-pyrrolo [2,3-d]pyrimidin-6-one 
• 1041703-69-8 C₁₅H₁₃N₇ 
• 875340-66-2 lithium 4-chloro-7-methyl-7H-pyrrolo[2,3-c]pyrimidine-6-carboxylate 
• 1266343-32-1 7-methyl-4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid 
• 1266343-34-3 N-(2-aminophenyl)-7-methyl-4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide 
• 1266341-96-1 5-(1H-1,3-benzodiazol-2-yl)-7-methyl-N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1266343-30-9 5-bromo-4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine 
• 1069473-61-5 4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid 
• 1337530-96-7 7-methyl-5-[1-(phenylacetyl)-2,3-dihydro-1H-indol-5-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1337532-51-0 5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1398560-46-7 4-((7-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-yl)oxy)aniline 
• 1337531-51-7 5-{1-[(2,5-difluorophenyl)acetyl]-2,3-dihydro-1H-indol-5-yl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 4-(pyrrolo[2,3-d]pyrimidine-4-yloxy)benzamide derivatives as potential antitumor agents

Cancer is a major cause of death worldwide. Small molecule inhibitors have become a major therapeutic treatment for cancer. In this study, a series of novel 4-(pyrrolo[2,3-d]pyrimidine-4-yloxy)benzamide derivatives were designed, synthesized and evaluated

PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS

The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, to pharmaceutical compositions comprising the compounds, to methods of using the compounds to treat physiological disorders such as cancer.

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.